EP3033150A4 - Administration of karenitecin for the treatment of advanced ovarian cancer, including chemotherapy-resistant and/or the mucinous adenocarcinoma sub-types - Google Patents
Administration of karenitecin for the treatment of advanced ovarian cancer, including chemotherapy-resistant and/or the mucinous adenocarcinoma sub-types Download PDFInfo
- Publication number
- EP3033150A4 EP3033150A4 EP14836702.2A EP14836702A EP3033150A4 EP 3033150 A4 EP3033150 A4 EP 3033150A4 EP 14836702 A EP14836702 A EP 14836702A EP 3033150 A4 EP3033150 A4 EP 3033150A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- karenitecin
- administration
- resistant
- types
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361865360P | 2013-08-13 | 2013-08-13 | |
PCT/US2014/050463 WO2015023551A1 (en) | 2013-08-13 | 2014-08-10 | Administration of karenitecin for the treatment of advanced ovarian cancer, including chemotherapy-resistant and/or the mucinous adenocarcinoma sub-types |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3033150A1 EP3033150A1 (en) | 2016-06-22 |
EP3033150A4 true EP3033150A4 (en) | 2017-06-28 |
Family
ID=52468603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14836702.2A Withdrawn EP3033150A4 (en) | 2013-08-13 | 2014-08-10 | Administration of karenitecin for the treatment of advanced ovarian cancer, including chemotherapy-resistant and/or the mucinous adenocarcinoma sub-types |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP3033150A4 (en) |
WO (3) | WO2015023553A2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013067050A1 (en) | 2011-10-31 | 2013-05-10 | University Of Utah Research Foundation | Genetic alterations in glioblastoma |
US20180301223A1 (en) * | 2015-04-14 | 2018-10-18 | University Of Utah Research Foundation | Advanced Tensor Decompositions For Computational Assessment And Prediction From Data |
CN105198790B (en) * | 2015-04-20 | 2018-02-16 | 范国煌 | Promote the tetracyclic compound of double negative t cells in-vitro multiplication |
EP3199641B1 (en) * | 2016-01-27 | 2021-09-29 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Means and methods for staging, typing and treating a cancerous disease |
CN107058315B (en) | 2016-12-08 | 2019-11-08 | 上海优卡迪生物医药科技有限公司 | Strike the siRNA for subtracting people PD-1, recombinant expression CAR-T carrier and its construction method and application |
AU2018289369A1 (en) * | 2017-06-20 | 2020-01-16 | Nantomics, Llc | Use of cell-free circulating rna (cfRNA) expression of PD-L1 and ERCC1 in plasma to monitor response to therapy in NSCLC |
CN113461952B (en) * | 2021-06-30 | 2022-07-01 | 广州市第一人民医院(广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院) | Active oxygen response type self-degradation polymer and preparation method and application thereof |
CN118103949A (en) * | 2021-09-15 | 2024-05-28 | 英飞凌科技有限责任公司 | Method for integrating SONOS into HKMG stream |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005113018A2 (en) * | 2004-04-27 | 2005-12-01 | Wellstat Biologics Corporation | Cancer treatment using viruses and camptothecins |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8293726B2 (en) * | 2005-12-02 | 2012-10-23 | Vianova Labs, Inc. | Treatment of cancer and other diseases |
US9023805B2 (en) * | 2010-09-16 | 2015-05-05 | Bionumerik Pharmaceuticals, Inc. | Increasing cancer patient survival time by administration of dithio-containing compounds |
-
2014
- 2014-08-10 WO PCT/US2014/050465 patent/WO2015023553A2/en active Application Filing
- 2014-08-10 WO PCT/US2014/050463 patent/WO2015023551A1/en active Application Filing
- 2014-08-10 WO PCT/US2014/050464 patent/WO2015023552A1/en active Application Filing
- 2014-08-10 EP EP14836702.2A patent/EP3033150A4/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005113018A2 (en) * | 2004-04-27 | 2005-12-01 | Wellstat Biologics Corporation | Cancer treatment using viruses and camptothecins |
Non-Patent Citations (4)
Title |
---|
ANNEMARIE H. VAN HATTUM ET AL: "New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer", INTERNATIONAL JOURNAL OF CANCER, vol. 88, no. 2, 15 October 2000 (2000-10-15), pages 260 - 266, XP055007980, ISSN: 0020-7136, DOI: 10.1002/1097-0215(20001015)88:2<260::AID-IJC18>3.0.CO;2-Q * |
MUNSTER PAMELA N ET AL: "Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma", EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 20, no. 11, November 2011 (2011-11-01), pages 1565 - 1574, XP002766330 * |
NAUMANN R WENDEL ET AL: "Management Strategies for Recurrent Platinum-Resistant Ovarian Cancer", DRUGS, ADIS INTERNATIONAL LTD, NZ, vol. 71, no. 11, 1 January 2011 (2011-01-01), pages 1397 - 1412, XP009165133, ISSN: 0012-6667, DOI: 10.2165/11591720-000000000-00000 * |
See also references of WO2015023551A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2015023551A1 (en) | 2015-02-19 |
WO2015023552A1 (en) | 2015-02-19 |
WO2015023553A3 (en) | 2015-04-23 |
EP3033150A1 (en) | 2016-06-22 |
WO2015023553A2 (en) | 2015-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3558324A4 (en) | Cyclic dinucleotide sting agonists for cancer treatment | |
EP3033150A4 (en) | Administration of karenitecin for the treatment of advanced ovarian cancer, including chemotherapy-resistant and/or the mucinous adenocarcinoma sub-types | |
EP3119908A4 (en) | Determining cancer aggressiveness, prognosis and responsiveness to treatment | |
EP3062808A4 (en) | Treatment of metastatic prostate cancer | |
EP3197518A4 (en) | Medicament preparation and treatment devices, methods, and systems | |
EP3071209A4 (en) | Use of sting agonist as cancer treatment | |
EP3004877A4 (en) | Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms | |
EP3076977A4 (en) | Combination therapy for treating cancer | |
EP3076972A4 (en) | Cancer treatment with combination of plinabulin and taxane | |
EP3033079A4 (en) | Methods for the treatment of her2 amplified cancer | |
MX2015011606A (en) | Methods of treating cancer and preventing cancer drug resistance. | |
EP3024375A4 (en) | Medical device, and the methods of using same | |
WO2014116833A3 (en) | Compositions and methods for detecting neoplasia | |
EP3432888A4 (en) | Treatment of cancer with tg02 | |
EP3307329A4 (en) | Cancer treatment and diagnosis | |
GB201512119D0 (en) | Security substrates,security devices and methods of manufacture thereof | |
WO2014138364A3 (en) | Methods of treating and preventing cancer drug resistance | |
EP3157336A4 (en) | Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer | |
EP2996721A4 (en) | Methods and compositions for prognosis, diagnosis and treatment of adam8-expressing cancer | |
EP3004396A4 (en) | Methods and compositions for the treatment of cancer | |
EP3062790A4 (en) | Pharmaceutical combinations for the treatment of cancer | |
EP3008212A4 (en) | Methods of treatment of cancer | |
EP3252171B8 (en) | Methods of treating cancer | |
EP3245204A4 (en) | Small molecules for the treatment of primary cancer and cancer metastasis | |
EP3217980A4 (en) | Methods of bladder cancer treatment with ciclopirox, ciclopirox olamine, or a ciclopirox prodrug |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20160310 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: HAUSHEER, FREDERICK H. |
|
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 45/06 20060101ALI20170130BHEP Ipc: A61K 31/185 20060101ALI20170130BHEP Ipc: A61K 31/4745 20060101AFI20170130BHEP Ipc: A61P 35/00 20060101ALI20170130BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20170526 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 45/06 20060101ALI20170519BHEP Ipc: A61K 31/185 20060101ALI20170519BHEP Ipc: A61K 31/4745 20060101AFI20170519BHEP Ipc: A61P 35/00 20060101ALI20170519BHEP |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/00 20060101ALI20170614BHEP Ipc: A61K 31/185 20060101ALI20170614BHEP Ipc: A61K 31/4745 20060101AFI20170614BHEP Ipc: A61K 45/06 20060101ALI20170614BHEP |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: CROWN BIOSCIENCE, INC. |
|
17Q | First examination report despatched |
Effective date: 20190405 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20190817 |